Join

Compare · AXDX vs PKI

AXDX vs PKI

Side-by-side comparison of Accelerate Diagnostics Inc. (AXDX) and PerkinElmer Inc. (PKI): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both AXDX and PKI operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
  • PKI is the larger of the two at $21.38B, about 108.5x AXDX ($197.2M).
  • PKI has more recent analyst coverage (17 ratings vs 1 for AXDX).
MetricAXDXPKI
Company
Accelerate Diagnostics Inc.
PerkinElmer Inc.
Price
$0.14+59.82%
$115.23-0.88%
Market cap
$197.2M
$21.38B
1M return
-93.21%
-
1Y return
-93.21%
-
Industry
Biotechnology: Laboratory Analytical Instruments
Biotechnology: Laboratory Analytical Instruments
Exchange
NASDAQ
NYSE
IPO
News (4w)
0
0
Recent ratings
1
17
AXDX

Accelerate Diagnostics Inc.

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was founded in 1982 and is headquartered in Tucson, Arizona.

PKI

PerkinElmer Inc.

PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as laboratory services. It also provides analytical technologies, solutions, and services for the environmental, food, and industrial markets that enable its customers to understand the characterization and health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology and drug discovery. The company serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

Latest AXDX

Latest PKI